The Beta Glucuronidase pipeline drugs market research report outlays comprehensive information on the Beta Glucuronidase targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Beta Glucuronidase pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Toxicology, Gastrointestinal, and Metabolic Disorders which include the indications Drug Toxicity, Chemotherapy Effects, Gastrointestinal, Inflammatory Bowel Disease, and Mucopolysaccharidosis VII (MPS VII) (Sly Syndrome ). It also reviews key players involved in Beta Glucuronidase targeted therapeutics development with respective active and dormant or discontinued products.
The Beta Glucuronidase pipeline targets constitutes close to six molecules. Out of which, approximately six molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Preclinical, and Discovery stages are 3, and 3 respectively.
Beta Glucuronidase overview
Beta Glucuronidase is an enzyme that in humans is encoded by a gene GUSB. The enzyme forms a homotetramer that is localized to the lysosome. Plays an important role in the degradation of dermatan and keratan sulfates. Mutations in this gene result in mucopolysaccharidosis type VII.
For a complete picture of Beta Glucuronidase’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
